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Targeting proteineprotein interactions has long been considered as a very difﬁcult if
impossible task, but over the past decade, front lines have moved. The number of suc-
cessful examples is exponentially growing. This review presents a rapid overview of recent
advances in this ﬁeld considering the strengths and weaknesses of the small molecule
approaches and alternative strategies such as the selection or design of artiﬁcial anti-
bodies, peptides or peptidomimetics.
© 2016 Academie des sciences. Published by Elsevier Masson SAS. This is an open access
article under the CCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).r é s u m é
Cibler les interactions proteineeproteine a longtemps ete considere comme une ta^che tres
difﬁcile, voire impossible, mais, depuis les dix dernieres annees, les lignes ont bouge. Le
nombre d’exemples de reussites s’accroît exponentiellement. Cette revue presente un
rapide panorama des avancees recentes dans ce domaine, considerant les forces et les
faiblesses de l’approche « petite molecule » ainsi que des strategies alternatives comme la
selection ou le design d’anticorps artiﬁciels, de peptides ou de peptidomimetiques.
© 2016 Academie des sciences. Published by Elsevier Masson SAS. This is an open access
article under the CCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Biology of the Cell
e Paris-Saclay, 91198,
chsenbein).
ed by Elsevier Masson SAS.1. Introduction: targeting proteineprotein
interactions
Pharmaceutical R&D undergoes a decline of productiv-
ity as the number of new drugs approved by the FDA
regularly decreases [1, 2]. Besides market forces and difﬁ-
culties such as demand and competition, pharmaceutical
R&D has become increasingly challenging. Advances in theThis is an open access article under the CC BY-NC-ND license (http://
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plex and multifactorial systems could be dissected in order
to identify reliable, safe and effective medicines [3, 4].
The origin of diseases often lies in a complex network of
biological interactions that need to be understood not only
at a clinical level, but also at phenotypic and molecular
levels. In that perspective, a wide range of ‘omics’ ap-
proaches (gene, RNA, protein, metabolism, etc.) have been
developed and data are accumulating with the hope that
they will become useful for personalized treatments [5].
Among them, proteomic approaches (including yeast two-
hybrid, afﬁnity puriﬁcation coupled to mass spectrometry,
and protein complementation assays) led to the establish-
ment of proteineprotein interaction (PPI) networks in
different model species and several human cell lines. These
data are centralized in open-access databases (reviewed in
[6]) and are regularly augmented by novel high- and low-
throughput experiments [7].
PPI networks are highly interconnected, some proteins
behaving as hubs, and involved in a large number of in-
teractions (on average, each protein has 5 partners and hub
proteins can associate with more than a hundred partners
[8]). A typical example of a hub protein is the human pro-
tein p53 shown as a central node in the network in Fig. 1
and which is found mutated in multiple types of cancers.
These interaction networks reorganize upon stress and in
numerous diseases. Mutations leading to the inhibition of
protein functions can also strongly impact PPI networks,Fig. 1. Interaction network and domain structure of the oncoprotein p53. Interacti
The lines indicate interactions between the proteins, with thickness of the lines reﬂ
is zoomed in on. The domain structure of p53 and structures of individual dom
interaction with MDM2, pdb 1ycr [145], DNA, pdb 1tsr 8023157 [146], and self-assbut it is still very difﬁcult to predict how far a PPI network
can be perturbed by such mutations. Predicting the
phenotypical consequences of a mutation in various cell
types or tissues also remains out of reach although some
studies are progressing toward that goal [9e11]. Interest-
ingly, protein mutants associated with a disease were
found to perturb PPI networks in a much larger proportion
compared to common variants (whose mutations were not
shown to be associated with any disease) [7] suggesting
that pathologies could likely be related to the perturbation
of PPI networks.
Deciphering the molecular logic associated with PPI
networks remains a major challenge for the next decade,
not only for fundamental research but also for pharma-
ceutical R&D. In this line, systematic knock-out or knock-
down of genes has been performed at the genome scale
in different model organisms of human cell types to
analyze functional and genetic interactions between genes
[12e15]. However, interpretation is hindered by the difﬁ-
culty in disentangling the pleiotropic effects of protein
depletion. Multiple pathways will likely be affected upon
inactivation of a hub protein. In parallel, for decades,
pharmaceutical R&D has generated molecules that are able
to inhibit the catalytic activity of many protein targets
associated with diseases or targeting G-protein coupled
receptors (GPCRs) that are the starting point of major and
complex cellular pathways. Such molecules can be used as
tools to perturb PPI networks and evaluate the associatedon network from the STRING database (http://string-db.org) for human p53.
ecting conﬁdence in the displayed interaction. The central region around p53
ains in interaction with partners are also represented (from left to right:
ociation, pdb 1c26 [147]).
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panies concentrated their efforts on targeting GPCRs that
are located on the surface of cells or intracellular enzymes
because these targets present cavities surrounding their
active sites and thus pre-existing small molecule binding
sites. Yet, these targets often occupy a central position in
PPI networks and their activity generally targets numerous
substrates sharing common properties and distributed all
over a PPI network. Consequently, enzyme-inhibiting
molecules often block the pocket of a large set of sub-
strates and affect many pathways downstream of the cat-
alytic reaction (as is the case of kinases for example). In
addition, inhibitory molecules can have limited speciﬁcity
and inhibit not only the targeted enzyme but its family of
paralogues leading to important side-effects [4].
An alternative to the pleiotropic effects of inhibitory
molecules on highly interconnected nodes in PPI networks
is the design of speciﬁc inhibitors of proteineprotein in-
teractions [16]. These tools not only help unraveling the
complexity of interconnected networks, but also provide
access to a much wider range of pharmaceutical targets
(called PPI targets) [17]. Molecules inhibiting a single PPI
are expected to act more speciﬁcally on biological path-
ways, improving the reliability of prognosis and reducing
side-effects [18].
In this review, we will provide an overview of recent
advances in the ﬁeld of PPI inhibition. A number of issues
are raised for identifying PPI inhibitors: the lack of starting
molecules, the size and ﬂatness of the surface to bind, the
composition of current chemical libraries, the assessment
of on-target effects. Over the past few years, these chal-
lenges have been tackled using a variety of strategies. We
will ﬁrst review the status of the ﬁeld in the development
of small molecules, and then discuss other tracks of
research relying on inhibitory proteins. In the last section,
peptide-based approaches will be presented, underscoring
their speciﬁc advantages over the two previous approaches
but also their current limitations.2. The small molecule approach
It has been considered a difﬁcult task to ﬁnd small
molecules competing with the binding of an intracellular
protein partner. One difﬁculty in designing small molecules
inhibiting a PPI is related to the size of the surface that
should be covered by the molecule, while inhibiting an
enzyme's active site is generally achieved through mole-
cules that occupy most of the space available in the func-
tional cavity of the enzyme. Compared to the active site of
an enzyme or the binding site of a receptor, PPIs are sta-
bilized through large interfaces formed by the burial of
protein atoms, up to thousands of square angstroms [19]. In
addition to the difﬁculty related to the size of the surface to
compete with, PPI interfaces represent diverse and multi-
faceted binding sites that impose signiﬁcant challenges in
conceiving efﬁcient inhibitors. Small molecule allosteric
inhibitors, targeting another site of the protein and capable
of inducing a conformational change leading to a loss of
interaction with the targeted partner, were also described
but they are not the majority [20].A second difﬁculty associated with the search for small
molecule PPI inhibitors, lies in the lack of catalytic activity
to screen when compared to the enzyme inhibitor devel-
opment, or the lack of simple functional assays for
screening agonists or antagonists for targeting G protein
related receptors (GPCR) [21]. In the case of PPI, high
throughput screens (HTSs) had to be revisited. Thermal
shift assays (measure of variation of the melting tempera-
ture of the protein alone and in the presence of a molecule)
[22], SPR (surface plasmon resonance) [23], FRET/BRET
(Fluorescence or Bioluminescence Resonance Excitation
Transfer) [24, 25], Elisa (Enzyme-linked immunosorbent
assay) [26], ﬂuorescence polarization [27], and Far western
[28] or other techniques (see [29] for a review), have been
developed but suffer from a large set of false positives (due
to protein aggregation, oligomer formation, and allosteric
binding for example). More sophisticated (and lower
throughput) biophysical methods that provide structural or
thermodynamic details of the molecule binding mode
(using isothermal calorimetry (ITC), Nuclear Magnetic
Resonance (NMR), and X-ray crystallography) are then
needed for further validation and characterization of po-
tential hits. Alternatively, high throughput cellular screens
measuring the loss of interaction using reverse two hybrid
or BRET have been developed and offer the advantage of
selecting only cell penetrable molecules [30, 31]. The latter
approaches require further validation to assess the “on
target” effect.
Favorable tracks for the development of small molecule
PPI inhibitors emerged in the eighties from the energetic
analysis of protein binding interfaces. Exploration of the
contribution of different contacts established upon binding
could be performed by alanine scanning of both partners.
Based on this technique, it has been shown that some
mutations of interfacial residues have little effect on the
binding afﬁnity of the two molecules while others have
major destabilizing effects [32e34]. Residues which largely
contribute to the binding afﬁnity have been called “hot-
spot” residues. A direct assumption from the “hot-spot”
analyses was that a small molecule interacting at the po-
sition of hot-spots should compete with the binding of the
cognate partner without necessarily covering the whole
surface of interaction (Fig. 2).
The experimental determination of hot-spots remains
however tedious and time consuming even if higher
throughput approaches havebeendeveloped since the early
alanine scans [35]. Based on the structure of two partners
forming a complex, several groups developed computa-
tional methods for the prediction of hot-spots. These
methods rely on different strategies that can be divided into
three main categories: methods based on dedicated energy
functions (such as FoldX, Rosetta, and PCRPi [36e38]),
methods based onmolecular simulations [39], andmethods
relying on machine learning algorithms (see for example
HSpred [40], and HotPoint [41]). On an average, these
methods present a success rate of about 80% in their pre-
dictions and combining them can even improve the accu-
racy of the hot-spot prediction (see [42] for a review).
As a positive step for the development of small molecule
PPI inhibitors, the position of hot-spots correlates with the
position of protein multiple binding sites. These sites are
Fig. 2. Hot-spots in proteineprotein interfaces. Structure of the human growth hormone (in green ribbon) and extracellular domain of its receptor (on the surface
with gray and light green color), pdb 3hhr [33, 148]. The binding interface of the receptor moiety is colored in light green. In the zoomed panel, hot-spots found
experimentally are shown in red, orange and yellow depending on the loss of binding energy associated with the mutation of the residue (red: more than
4 kcal mol1, orange: more than 2 kcal mol1, yellow: more than 1 kcal mol1).
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homologs, bound either to small molecules or to another
protein in the protein data bank (PDB) [43, 44]. They
correspond to “ sticky zones ” of proteins playing a central
role in stabilizing interactions with the natural protein
partners and also prone to bind small molecules. These
sticky zones have recently been shown to also concentrate
the binding energy of inhibitors, opening promising de-
velopments for the rational selection of binding molecules
[45, 46].
Hot-spots are generally clustered at the center of small
to medium size binding interfaces (250e900 Å2). This
property facilitates their targeting by small molecules. A
typical example is the inhibition of bromo-domains [47].
These domains speciﬁcally bind linear protein motifs con-
taining acetylated lysines. The modiﬁed residue (acetylated
lysine) is inserted into a well-deﬁned pocket at the surface
of bromo-domains and is recognized by strictly conserved
residues. Residues surrounding the pocket participate in
the binding afﬁnity and speciﬁcity (Fig. 3). Inhibitors of
bromo-domains have recently been developed with
remarkable success [48e51] (see [52] for a review).
In larger proteineprotein interfaces, hot-spots can be
more distributed over the interface with signiﬁcant dis-
tance between them. They also cover a more complex
combination of chemical functions, increasing the difﬁculty
of ﬁnding a molecule interfering with all the hot-spots. As a
ﬁrst step in the development of computational tools for
selecting PPI inhibitors, several groups analyzed the
chemical properties of the growing number of small
molecule PPI inhibitors already discovered. Until now,more than 40 PPIs have been successfully targeted, and at
least 3 databases are dedicated to modulators of PPI: the
2P2I database [53, 54], TIMBAL [55, 56] and iPPI-DB [57].
PPI inhibitors exhibit a signiﬁcantly larger size and mo-
lecular weight than traditional drugs (MW > 400 Da). PPI
inhibitors are also more hydrophobic with a ALogP > 4;
they contain a larger number of hydrogen bonds (HBA > 4)
and at least four rings [58e60]. These chemical character-
istics are clearly different from those usually used for
selecting drug-like compounds, the so-called Lipinski rules
[61]. Such deviation from the classical characteristics points
out the necessity of assembling banks of molecules dedi-
cated to PPI screenings, containing a higher chemical di-
versity and greater complexity than banks used for
traditional drug design. Further exploration of natural
products should typically help diversifying and com-
plementing such banks of compounds [62]. Computational
tools dedicated to the search for PPI inhibitors were also
combined with experimental screens to accelerate and
reduce the cost of screens. This strategy was particularly
powerful in cases where no previously known inhibitor
could be used as a starting point in a structure-based
research program [63e65].
An alternative approach to the complexiﬁcation of
banks of compounds is the so-called “fragment approach”.
Instead of selecting a starting molecule of relatively high
molecular weight, it consists of searching a set of simple
small molecules (fragment) with low afﬁnity for one of the
partners and builds the inhibitor step by step through a
structure-based strategy [66e69]. For this strategy, iden-
tiﬁcation of binding hot-spots is particularly useful to
Fig. 3. Small molecule inhibitor of the interaction between bromo-domains and acetylated histones. A: Structure of the ﬁrst bromodomain of human BRD4 in
interaction with a diacetylated histone H4 peptide H4K5acK8ac), pdb 3uvw [149]. The bromodomain is shown in a surface representation (in gray and light pink
for residues in contact with the histone peptide). The histone peptide is shown in purple sticks. B: Structure of the ﬁrst bromodomain of human BRD4 in
interaction with the small molecule inhibitor JQ1, pdb 3mxf [48]. The surface of the bromodomain in contact with JQ1 (in red sticks) is colored in dark pink. C:
Chemical structure of the small molecule JQ1 [48].
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efﬁciently compete with the cognate partner. Because the
afﬁnity of the ﬁrst selected compound is expected to be
rather low, screens based on inhibiting a speciﬁc PPI as
mentioned above are not the most adapted. Direct struc-
tural screens in primary screens using X-ray crystallog-
raphy or NMR have been successfully employed. The
starting molecule can then be directly selected based on its
binding site. Even if the afﬁnity of a starting compound
typically falls in the milli-molar range, it was found to be
enough for starting an optimization procedure by
expanding the molecule size while simultaneously opti-
mizing the binding afﬁnity [68, 70]. Crystal contacts can
also be used to ﬁnd new binding sites [71], and increase the
molecule size by tethering fragments. Another successful
strategy to select a ﬁrst fragment was to tether the mole-
cule via an SS bond at a position close to the targeted PPI
interaction [72, 73]. In this strategy, the presence of a co-
valent bond between the target and the initial fragment
compound can help obtaining the structure of the complex
[74].
3. The protein approach
When the targeted interaction includes a large PPI
interface, alternatives to the small molecule approach were
also envisaged. A ﬁrst category of developments was theconception of monoclonal antibodies competing with the
PPI formation. This approach, necessitating the ‘humani-
zation’ of immunoglobulins to prevent an immune reac-
tion, was remarkably successful, so that each year, tens of
new antibodies started clinical trials [75] or reached FDA
drug approvals [76e78] for therapeutic applications or
diagnostic purposes. The ﬁrst inhibitory antibody was
designed using phage display (Fig. 4A) [79]. This technique
rapidly allowed the design of thousands of tightly binding
immunoglobulin domains with even higher afﬁnity than
those observed in nature [80]. Other approaches used im-
munization of humanized murine models [75]. The
exploitation of simpler immunoglobulin systems such as
the nanobodies found in camelids should give rise to more
stable and simpler molecules (Fig. 4B) [81, 82]. Such
nanobodies were found to be powerful for targeting G-
protein coupled receptors (GPCRs) and used as research
tools, diagnostics or therapeutics [81]. Scaffolds other than
the immunoglobulin fold were also developed for targeting
PPIs and protein binding in general. They include repetitive
sequences also called artiﬁcial antibodies (Darpins, Fig. 4D,
[83, 84], Alpharep, Fig. 4E, [85, 86] and also more diverse
scaffolds, Fig. 4C [87, 88]).
Computational methods also contributed signiﬁcantly
to this ﬁeld. Modeling and design tools such as the Rosetta
suite have reached sufﬁcient accuracy to be able to guide
the rational design of binders [89]. The combination of
Fig. 4. Structure of selected or designed proteins (in rainbow) bound to their target (in gray). A: Antibody against a 24-amino acid peptide from the third variable
(V3) loop of human immunodeﬁciency virus-type 1 (HIV-1) gp 120, pdb 1acy [150]. B: Structure of the anti-HIV A12 VHH of llama antibody in complex with
C1086 gp120, pdb 3rjq. C: Structure of the viral HIV-1 gp120 protein engineered for binding the neutralizing antibody, pdb 4jpk [90]. D: Selected ankyrin repeat
binder of the kinase ERK, pdb 3zu7 [83]. E: Structure of an artiﬁcial helicoidal repeat protein (alphaRep) selected for binding an helical synthetic protein, pdb
4jw2 [85].
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technologies such as ribosome or yeast display coupled to
deep sequencing technologies open great perspectives for
the diversiﬁcation of the classes of binders [88e91].
Computational methods can also be used to reduce the
immunogenicity of designed proteins [92].
Natural, engineered or artiﬁcial antibodies designed for
PPI inhibition were generally conceived to compete with
the cognate partner (orthosteric mechanism); but in a few
cases, they also act via an allosteric mechanism [93].
However, the latter mechanism of action is difﬁcult to
rationalize or predict because it implies subtle conforma-
tional changes in the targeted protein.
Finally, the major limitation of antibodies, nanobodies
and other proteins selected for tight binding of a target
remains to be the difﬁculty to bring these proteins into
cells. Their applications remain mainly limited to extra-
cellular targets.
4. The peptide/peptidomimetic approach
Peptides are natural compounds sufﬁciently large to
potentially block an interaction and hit several hot-spots.
However, when targeting intracellular PPIs, inhibitorypeptides will have to cross the cell membrane. Major ad-
vances have been made in the elaboration of the so-called
cell penetrating peptides (CPPs) which brought signiﬁcant
progress for the development of intracellular peptide-like
drugs. Numerous academic laboratories, but also a
growing number of companies, are working on different
methods for developing cell-permeable or potential PPI
inhibitor peptides [18]. The capacity of particular peptide
sequences to penetrate cells was ﬁrst discovered in small
proteins acting as neurotransmitters (penetratin, [94]) and
viral proteins (tat [95]). The penetration mechanism was
then intensively studied, highlighting a variety of mecha-
nisms depending on the type of CPP that are still under
investigation [95e98]. Entry into cells involves endosomal
uptake but also direct membrane crossing. CPP properties
were transferred to active inhibitory peptides by adding a
CPP sequence at the N or C-terminus [99] or by modifying
the peptide's positively charged residues at positions that
do not interfere with the binding of the target [100].
Penetrating sequences were varied and optimized
[101e103] and also introduced from chemical modiﬁca-
tions [104].
One point of great interest about the peptide strategy is
that the afﬁnity of the peptide for the target can be
Fig. 5. Structure of helical peptidomimetics. A: Crystal structure of the HIV-1 neutralizing antibody 4E10 Fab fragment (in gray ribbon) in complex with a
hydrocarbon-stapled peptide (in blue sticks), pdb 4nhc [118]. B: Analogues of the Bim BH3 domain with an a/b-backbone pattern (in light blue sticks) in complex
with Bcl2-like protein 1 (in gray ribbon), pdb 4a1u [151], C: urea based helical structure [121], D: Aryl-linked imidazolidin-2-ones as non-peptidic b-strand
mimetics [129], E: functionalised aromatic oligamide as helical mimetics [130].
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antibodies, i.e. molecular biology, directed evolution,
computational design tools, etc. The latter computational
approaches need speciﬁc protocols, considering the
increased ﬂexibility of peptides compared to globular
proteins [105e109]. Another advantage of the peptide
strategy is the simple synthesis step which beneﬁts from
decades of solid-phase chemical synthesis developments.
High-throughput approaches, such as peptide arrays, for
the detection of ﬁrst peptide hits or the investigation of
peptide selectivity for homologous targets can thus be
easily set up [110, 111].
The main limitation of peptides as drugs remains
however their high susceptibility to proteases in vivo, even
if a rapid internalization was shown to bring partial pro-
tection [112]. To overcome this obstacle commonly associ-
ated with peptide-based drugs, a large set of chemical
modiﬁcations have been presented in the literature, con-
taining increasing deviations from the natural peptide
scaffold, with some remarkable successes for PPI inhibition.
Introduction of non-natural side-chains was performed toincrease the afﬁnity by optimizing contacts for the target
while increasing solubility or limiting proteolysis [113]. D-
aminoacids can be introduced at some positions with
limited perturbations for the peptide conformation [114,
115]. Peptide cyclization has also been performed through
the design of simple cyclic peptides [113, 116] or the
introduction of staples (Fig. 5A). Helix staples were shown
not only to stabilize helical conformations but also to favor
cell penetration [104,117e119] and protect peptides from
proteolysis. More divergent from natural peptides, oligo-
mers of non-alpha-amino-acid backbones have been
designed to preserve their capacity to form well-deﬁned
compact structures. These so-called foldamers [120] can
be designed to maintain the position of anchor residues for
interacting with the protein target (Fig. 5) [119,121e127]
while exhibiting more than 100-fold higher resistance to
proteolysis [119,124e128]. Even less peptide-like,
numerous strategies of non-peptidic foldamer alpha-helix
mimetic scaffolds have been presented in the literature,
such as terphenyl-based, terephthalamide-based, and Aryl-
linked imidazolidin-2-ones[129] or various oligoamide
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inhibited PPIs, such as calmodulin and small musclemyosin
light chain kinase [132], Bax-BclXL [133, 134], the VEGF
receptor [135] or p53-mdm2 [136], see [123, 137, 138] for
reviews. Interestingly, synthesis of foldamers can be, in
some cases, adapted to solid-phase synthesis, facilitating
their production and puriﬁcation [139, 140]. In addition,
computational tools are currently developed for the
rational design of foldamers [141, 142]. All these efforts
should pave the way for inhibiting any PPI target with no
limitation in the size and composition of the interface to
compete with.
5. Conclusion and further challenges
Inhibiting proteineprotein interactions has become a
reality for a signiﬁcant number of examples and could be
envisioned as a more general strategy for deciphering the
molecular logic associated with PPI networks, or for ther-
apeutic applications. Depending on the size of the targeted
interface, the afﬁnity of the interaction and the position of
hot-spots, different strategies can be envisioned. Small
molecules are more suitable for small and compact in-
terfaces whereas inhibition of large interfaces is more likely
achievable by using peptidomimetics. Antibodies or artiﬁ-
cial binders could be considered the approach of choice for
targeting extracellular receptors. Remarkably, these stra-
tegies are not always independent, since efﬁcient pepti-
domimetics or small molecules were successfully derived
from peptides (as for example the mdm2-p53 interaction
[113, 142, 143], or the Notch complex [104]), but also from
antibodies [116, 118]. In some examples, peptides were
used as ﬁrst molecules to validate the target and facilitate
the search for active peptidomimetics or small molecules
[144].
Some important challenges still remain. Regarding the
exploration of PPI networks, high throughput data
including dynamic and spatial information of PPIs could
help to unravel molecular mechanisms associated with PPI
networks. Modeling tools are also to be developed, at least
for simple networks, to be able to exploit all these high
throughput data. An open question regarding the huge
amount of data that can be generated by high throughput
approaches is whether it is reasonable to collect HTS data in
all tissues of each patient.
Considering the search for PPI inhibitors, enlarging the
chemical space for efﬁcient screening of small molecules is
needed, and grouping together dedicated banks should be
favored. Nucleic-acid aptamers could also be selected to
bind protein surfaces and inhibit proteineprotein in-
teractions. Developments for the design of a broad range of
peptidomimetics are still in progress and should contribute
to increase the chemical space of molecules for targeting
PPIs. A major obstacle for such molecules could be the
immunologic response. New delivery systems avoiding
broad distribution, delivering to the right target, and fa-
voring transport across biological barriers will also have to
be further developed. Finally, it has to be mentioned that, if
disruption of PPIs is now considerably progressing, mole-
cules able to restore a PPI lost due to a pathogenic mutation
are still restricted to exceptional cases. Such moleculeswould be of great interest to develop new drugs in genetic
diseases and this is probably a forthcoming important
challenge in the ﬁeld.
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